|
|
New targets in lipid management
|
|
|
|
Novel Approaches to Modify Lipids and Lipoproteins
|
|
|
|
Statin Prescription in the UK
|
|
|
|
Percentage of the UK-population with TC > 5 mmol/l
|
|
|
|
All-Cause Mortality in the UK in those < 75 Years
|
|
|
|
New Approaches to LDL Reduction
|
|
|
|
Mipomersen: Apo B-100 as a Target
|
|
|
|
Overview of Mipomersen
|
|
|
|
Antisense
|
|
|
|
Heterozygous Familial Hypercholesterolemia
|
|
|
|
Mipomersen Significantly Reduced LDL-C
|
|
|
|
Distribution of LDL-C % Change From Baseline
|
|
|
|
The Rationale
|
|
|
|
Selective Thyroid Receptor Agonist Provides New Treatment Opportunities
|
|
|
|
Eprotirome is…
|
|
|
|
Eprotirome Monotherapy Efficiently Lowers LDL-C
|
|
|
|
LDL-C Mean % Change from Baseline
|
|
|
|
PCSK9 Rapid Pace of Research
|
|
|
|
New Approaches for Raising HDL
|
|
|
|
CETP Levels and CAD risk
|
|
|
|
Anacetrapib Dose Ranging Study
|
|
|
|
Future
|
|
|
|
Niacin Flushing Pathway
|
|
|
|
An Overview of the Niacin-Induced Flushing Pathway
|
|
|
|
Factorial Study: Lipid Efficacy
|
|
|
|
HPS2-THRIVE
|
|
|
|
ApoA1 Based Therapies
|
|
|
|
Cerenis HDL (CER-001)Homogeneous Drug Product
|
|
|
|
CER-001 Mobilizes Cholesterol in Rabbits
|
|
|
|
CHI SQUARE Study Design
|
|
|
|
CHI-SQUARE Study Design
|
|
|
|
IVUS clinical trial using selective delipidated HDL
|
|
|
|
IVUS Clinical Trial Using Selective Delipidated HDL
|
|
|
|
Results of the IVUS Clinical Trial Using Selective Delipidated HDL
|
|
|
|
New Approaches for Reduction of TG rich Lipoproteins
|
|
|
|
Apolipoprotein C-III Key Regulator of Serum Triglyceride Levels
|
|
|
|
Dose-dependent Reduction in Hepatic ApoC-III mRNA Levels
|
|
|
|
Changes in Major Lipid Classes Over 12 Weeks in HTG Rhesus Plasma
|
|
|
|
New Approaches for Reduction of Inflammation
|
|
|
|
The Balance of IL-1 and IL-1Ra
|
|
|
|
Canakinumab
|
|
|
|
Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
|
|
|
|
Conclusion
|
|
Deel deze pagina met collega's en vrienden: